{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T11:27:16Z","timestamp":1772105236844,"version":"3.50.1"},"reference-count":41,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,1,11]],"date-time":"2020-01-11T00:00:00Z","timestamp":1578700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["164587"],"award-info":[{"award-number":["164587"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of the study was to investigate whether lamivudine (3TC) or emtricitabine (FTC) use following detection of M184V\/I is associated with better virological outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We identified people with viruses harbouring the M184V\/I mutation in UK multicentre data sets who had treatment change\/initiation within 1\u00a0year. We analysed outcomes of viral suppression (&lt;\u00a0200\u00a0HIV\u20101 RNA copies\/mL) and appearance of new major drug resistance mutations (DRMs) using Cox and Poisson models, with stratification by new drug regimen (excluding 3TC\/FTC) and Bayesian implementation, and estimated the effect of 3TC\/FTC adjusted for individual and viral characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included 2597 people with the M184V\/I resistance mutation, of whom 665 (25.6%) were on 3TC and 458 (17.6%) on FTC. We found a negative adjusted association between 3TC\/FTC use and viral suppression [hazard ratio (HR)\u00a00.84; 95% credibility interval (CrI) 0.71\u20130.98]. On subgroup analysis of individual drugs, there was no evidence of an association with viral suppression for 3TC (<jats:italic>n<\/jats:italic>\u00a0=\u00a0184; HR\u00a00.94; 95% CrI 0.73\u20131.15) or FTC (<jats:italic>n<\/jats:italic>\u00a0=\u00a0454; HR\u00a00.99; 95% CrI 0.80\u20131.19) amongst those on tenofovir\u2010containing regimens, but we estimated a reduced rate of viral suppression for people on 3TC amongst those without tenofovir use (<jats:italic>n<\/jats:italic>\u00a0=\u00a0481; HR 0.71; 95% CrI 0.54\u20130.90). We found no association between 3TC\/FTC and detection of any new DRM (overall HR\u00a00.92; 95% CrI 0.64\u20131.18), but found inconclusive evidence of a lower incidence rate of new DRMs (overall incidence rate ratio 0.69; 95% CrI 0.34\u20131.11).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We did not find evidence that 3TC or FTC use is associated with an increase in viral suppression, but it may reduce the appearance of additional DRMs in people with M184V\/I. 3TC was associated with reduced viral suppression amongst people on regimens without tenofovir.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.12829","type":"journal-article","created":{"date-parts":[[2020,1,12]],"date-time":"2020-01-12T03:17:36Z","timestamp":1578799056000},"page":"309-321","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Continuation of emtricitabine\/lamivudine within combination antiretroviral therapy following detection of the M184V\/I HIV\u20101 resistance mutation"],"prefix":"10.1111","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8705-3281","authenticated-orcid":false,"given":"OT","family":"Stirrup","sequence":"first","affiliation":[{"name":"Institute for Global Health University College London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Asboe","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster Hospital London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Pozniak","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster Hospital London UK"},{"name":"London School of Hygiene &amp; Tropical Medicine London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5173-2760","authenticated-orcid":false,"given":"CA","family":"Sabin","sequence":"additional","affiliation":[{"name":"Institute for Global Health University College London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Gilson","sequence":"additional","affiliation":[{"name":"Institute for Global Health University College London London UK"},{"name":"CNWL Mortimer Market Centre London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NE","family":"Mackie","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Tostevin","sequence":"additional","affiliation":[{"name":"Institute for Global Health University College London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Hill","sequence":"additional","affiliation":[{"name":"Institute for Global Health University College London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DT","family":"Dunn","sequence":"additional","affiliation":[{"name":"Institute for Global Health University College London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,1,11]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.11.3377-3383.2003"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02154-08"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05487-11"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000131355.44834.e4"},{"issue":"10","key":"e_1_2_6_6_1","first-page":"556","article-title":"The M184V mutation: what it does, how to prevent it, and what to do with it when it's there","volume":"16","author":"Gallant JE","year":"2006","journal-title":"AIDS Read"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2.1.147"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.2.747-754.2003"},{"issue":"9","key":"e_1_2_6_9_1","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/S2352-3018(17)30069-3","article-title":"Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second\u2010line maintenance treatment for HIV\u20101\u2010infected patients in sub\u2010Saharan Africa (ANRS12 286\/MOBIDIP): a multicentre, randomised, parallel, open\u2010label, superiority trial","volume":"4","author":"Ciaffi L","year":"2017","journal-title":"Lancet HIV"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512213332502"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03540020040027"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000218542.08845.b2"},{"issue":"6","key":"e_1_2_6_13_1","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/135965350601100608","article-title":"A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine\u2010containing regimen: the COLATE trial","volume":"11","author":"Fox Z","year":"2006","journal-title":"Antivir Ther"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5253.1282"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2376-2379.2003"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001191"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000243211.36690.d5"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2004.00197.x"},{"key":"e_1_2_6_19_1","first-page":"132","article-title":"2017 update of the drug resistance mutations in HIV\u20101","volume":"24","author":"Wensing A","year":"2017","journal-title":"Top Antivir Med"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-6646-9_5"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-122"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6191"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v076.i01"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-018-0198-7"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu046"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12534"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001660"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00096-1"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70736-4"},{"issue":"12","key":"e_1_2_6_30_1","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cid\/cix734","article-title":"Dual therapy with darunavir and ritonavir plus lamivudine vs triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of human immunodeficiency virus type 1 viral suppression: randomized, open\u2010label, noninferiority DUAL\u2010GESIDA 8014\u2010RIS\u2010EST45 trial","volume":"65","author":"Pulido F","year":"2017","journal-title":"Clin Infect Dis"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32462-0"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12348"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.15995.1"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy113"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(14)00061-7"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30065-6"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12024"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30180-7"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30087-5"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2017.0290"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1998.14.249"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199907300-00011"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhiv.12829","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12829","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.12829","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T03:50:13Z","timestamp":1694058613000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.12829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,11]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1111\/hiv.12829"],"URL":"https:\/\/doi.org\/10.1111\/hiv.12829","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,11]]},"assertion":[{"value":"2019-11-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}